Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Darmstadt – page 36

1 664 clinical trials in Darmstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Darmstadt at a glance
1 664
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 664 trials in Darmstadt

Open in trial search

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Long-Term Safety Study of Berotralstat for Patients with Hereditary Angioedema from Previous Trials

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Berotralstat
  • Sponsor:Biocryst Pharmaceuticals Inc.

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Acute leukaemia

Recruiting

Study on the Safety and Tolerability of SNDX-5613 for Patients with Relapsed or Refractory Acute Leukemias

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Revumenib
  • Sponsor:Syndax Pharmaceuticals Inc.

Leukaemia

Recruiting

Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Heinrich-Heine-Universitaet Duesseldorf

Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Icahn School Of Medicine At Mount Sinai

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Osteoarthritis

Recruiting

Study on Shortened Anticoagulation with Rivaroxaban for Blood Clot Prevention in Patients Undergoing Hip Replacement Surgery

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Study on the Use of Human Apotransferrin for Treating Patients with Atransferrinemia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Human Apotransferrin
  • Sponsor:Prothya Biosolutions Netherlands B.V.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Darmstadt

What the registry says about research in the country

01 Dermatology Studies

Extensive research focusing on plaque psoriasis and hidradenitis suppurativa, evaluating new therapeutic approaches for chronic skin conditions. Multiple trials are testing novel treatments for moderate to severe cases.

  • Psoriasis Management
  • Hidradenitis Suppurativa Treatment
  • Atopic Dermatitis Therapy

Several innovative compounds being tested including ESK-001, remibrutinib, and JNJ-77242113.

02 Respiratory Medicine

Comprehensive studies addressing severe asthma and COPD, with particular attention to treatments for patients with eosinophilic phenotypes and those requiring advanced care options.

  • Asthma Control
  • COPD Management
  • Chronic Cough Treatment

Trials evaluating new inhalation therapies and biological treatments for better disease control.

03 Oncology Research

Advanced studies in acute myeloid leukemia, investigating combination therapies for patients ineligible for intensive chemotherapy. Focus on targeted treatments for specific genetic mutations.

  • AML Treatment
  • Novel Drug Combinations
  • Targeted Therapies

Investigating innovative approaches including revumenib in combination with established treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.